Group 1 - The stock price of Wuzhou Medical (301234) showed volatility from February 4 to February 11, 2026, with a closing price of 42.01 yuan on February 10, reflecting a daily increase of 0.26%, and a latest price of 41.80 yuan on February 11, indicating a decrease of 0.50% [1] - On February 10, the net outflow of main funds was 362.88 thousand yuan, accounting for 14.62% of the total transaction amount, with an overall trend of net outflow in the past five days [1] - The technical indicators show that the current stock price is close to the 20-day resistance level of 42.24 yuan, with a recent MACD indicator showing a golden cross signal, although the distribution of shares is scattered, indicating low control by main funds [1] Group 2 - Recent policies in the medical industry may indirectly impact Wuzhou Medical, with the launch of the China International Medical Equipment and Devices Trading Platform on February 10, aimed at promoting global trade in medical devices, which could benefit the company as its overseas revenue accounts for 96.88% based on the 2024 annual report [2] - The Ministry of Industry and Information Technology and other departments have strengthened policy support for low-altitude economy and AI medical fields, although the company's business is not directly involved in these hot concepts [2] Group 3 - Wuzhou Medical released its 2025 annual performance forecast on January 29, 2026, expecting a net profit range of 16 million to 21 million yuan, representing a year-on-year decline of 47.46% to 59.97%, primarily due to fluctuations in its main business [3] - The company's third-quarter report for 2025 indicated a year-on-year decrease of 46.09% in net profit attributable to the parent company [3]

2月10日，政协第五届江门市蓬江区委员会第六次会议召开，蓬江正式迈入两会时间。与会人员齐聚一 堂、共商发展，携手为蓬江高质量发展绘制美好蓝图。会议期间，政协委员围绕蓬江区政府工作报告， 结合自身深耕领域谈发展感受、献务实良策，从科创赋能产业、空间布局优化到跨区域协同发展等多个 维度，为蓬江高质量发展出谋划策、凝聚智慧与力量。 李镇强： 深化港江融合 激活发展新动能 "听完报告后我非常振奋！这一年蓬江的发展非常务实且有成效。"民建江门市蓬江总支主委，江门市蓬 江区自然资源局总工程师、三级主任科员章海燕聆听政府工作报告后，对蓬江过去一年优化国土空间布 局、保障产业发展用地的工作成效倍感认可。她谈到，过去一年，区委、区政府聚焦国土空间布局和产 业用地，坚持规划引领、全域土地整治，通过增量提升、存量盘活全面激活土地要素，紧扣 "制造业当 家"啃下"工改" 硬骨头，杜阮万洋科技城、荷塘万洋光电产业园改造老旧厂房等项目的落地，正是蓬江 土地要素保障工作成效的生动体现，而蓬江能成功跻身"千亿城区"，充足的空间要素保障更是打下了坚 实基础。 当前蓬江全力发展高端制造、咖啡茶饮等特色产业，如何在严守耕地红线的前提下提供更精准的 ...

来源：美通社 北京2026年2月11日 /美通社/ -- 当课堂的关键知识点讲解被错过，当同伴的欢笑像隔着一层模糊的"声音 屏障"，听损学子正独自承受着比学业更重的压力：听不清、听得累。这让他们在课堂上费力追赶，消 耗着本应用于思考的精力，让他们在社交中悄悄退缩，埋下自卑的种子，甚至成为亲子间误解与摩擦的 导火索，让青春期本就敏感的内心更添一层孤寂。更令人担忧的是，长此以往容易形成负向循环：听得 越吃力，越发回避交流；越少表达，学习与社交的信心越难以建立；而自信的消磨，又反过来让他们更 不愿主动去"听"和"说"，影响学习和社交。有多少家人、朋友能敏感洞察、清晰理解这不经意的细节是 来自于听不好的困扰呢？ 挣脱"听力内耗"：把精力还给思考与创造 听损少年需要什么样的"听觉伙伴"呢？哪怕身处不同噪声环境，面对不同交谈对象的口型、语速、频率 等，也能听清听懂；能够敏感感知环境变化，捕捉细小有意义的声音，享受不同环境中的安全性，在社 交中敏感洞察，沉浸式融入；在各种无线配件的助力下，通过蓝牙数据底层直连，摆脱环境干扰，直接 在"耳边倾听"想听的声音，例如在大礼堂后排，也能体验演讲者如在耳边讲述的零距离清晰声音；智能 ...

经济观察网南微医学(688029)在2026年有两大关键事件值得关注。其泰国生产基地预计于2026年年初落 成启用，旨在优化全球供应链布局，主要面向欧美市场。同时，公司计划在2026年推出二代胆道镜等可 视化创新产品，以拓展临床应用领域。 创新产品上市计划：公司二代胆道镜等可视化创新产品预计在2026年推出，以进一步拓展临床应用领 域。 以上内容基于公开资料整理，不构成投资建议。 公司项目推进 泰国生产基地落成启用：南微医学泰国生产基地预计于2026年年初落成并投入使用，该基地旨在优化全 球供应链布局，主要供应欧美市场。 产品研发进展 ...

经济观察网振德医疗（603301）在2026年2月11日发布的股票交易异常波动公告中，已对近期股价异动 情况进行了说明。根据公告内容，公司并非"避谈"，而是通过正式渠道回应了市场关切。 股票近期走势 行业板块情况 此次股价异动前，市场曾关注2025年9月孙纪木受让公司5%股权的事件，以及公司2025年前三季度净利 润同比下滑33.91%但第三季度扣非净利润同比增长2.0%等基本面信息。然而，公司在最新公告中强 调，这些均为已披露信息，并非本次异常波动的未披露原因。振德医疗的公告内容符合监管要求，对异 常波动的核查情况进行了披露。 公司股票在2026年2月6日、2月9日和2月10日连续三个交易日内收盘价格涨幅偏离值累计超过20%，触 发了上海证券交易所的股票交易异常波动情形。截至2026年2月11日最新数据，该股当日收盘价为92.20 元，单日涨幅3.88%，连续两个交易日涨停后继续上涨。 以上内容基于公开资料整理，不构成投资建议。 公司状况 振德医疗在公告中明确表示：生产经营正常：经公司自查，目前生产经营活动正常，外部经营环境和行 业政策未发生重大变化。披露事项明确：近期唯一需披露的重大事项是回购股份用途变更 ...

医疗器械 渠道积淀筑底，自研驱动与战略拓展打开成长空间 可孚医疗（301087.SZ） 证券研究报告/公司深度报告 2026 年 02 月 11 日 | 评级： | 买入（首次） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | | | 营业收入（百万元） | 2,854 | 2,983 | 3,384 | 4,098 | 5,100 | | 分析师：祝嘉琦 | | 增长率 yoy% | -4% | 5% | 13% | 21% | 24% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | 254 | 312 | 359 | 436 | 551 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | -16% | 23% | 15% | 22% | 26% | | | | 每股收益（元） | 1.22 | 1.49 | 1.72 | 2.09 | ...

Core Viewpoint - Mingzhi Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, attracting attention due to its impressive financial metrics and leading position in the disposable endoscope market, while also facing challenges such as high customer concentration, declining cash flow, and increasing market competition [1][3]. Financial Performance - The company reported a gross margin of 72.62% and a net margin of 47.26% for 2024, with a significant increase in gross margin from 69.1% in 2023 to 73.7% in the first nine months of 2025, indicating strong profitability driven by vertical integration [2][4]. - Revenue for 2024 is projected at 1.41 billion RMB, a 4.4% increase from 1.35 billion RMB in 2023, while revenue growth slowed to 3.86% in the first nine months of 2025 compared to the same period in 2024 [3][4]. - Taxable profit reached 81.83 million RMB in 2024, a 28.0% increase from 63.92 million RMB in 2023, but fell by 16.2% to 58.93 million RMB in the first nine months of 2025 [4][6]. Market Position - Mingzhi Technology ranks among the top three brands in the disposable ureteroscope market in the U.S., Europe, and Japan, showcasing its international competitiveness in a highly regulated environment [3][9]. - The disposable endoscope market is expected to grow from approximately 2 billion USD in 2023 to over 6 billion USD by 2030, with a compound annual growth rate exceeding 17% [8][9]. Competitive Landscape - The market is dominated by major players such as Ambu, Boston Scientific, and Olympus, which collectively hold over 40% of the global market share, presenting significant competitive challenges for Mingzhi Technology [9][10]. - The company faces increasing pressure from local competitors in China, such as Kaili Medical, which has entered the disposable ureteroscope segment, intensifying competition [9][10]. Operational Challenges - Customer concentration remains high, with the top five customers accounting for 62.6% to 69.9% of sales from 2023 to the first nine months of 2025, indicating a dependency risk [10][11]. - The company relies heavily on distributors for revenue, with 92.8% of income coming from this channel in 2024, which may limit direct customer engagement and profit margins [10][11]. - Cash flow has deteriorated, with operating cash flow declining by 19.45% in the first nine months of 2025, attributed to increased inventory and extended accounts receivable collection periods [11][12]. Strategic Outlook - Mingzhi Technology's financial and operational indicators suggest it is at a critical juncture, needing to balance high profitability with sustainable growth strategies amid intensifying competition [7][11]. - The ability to manage operational and financial risks while leveraging technological innovation and maintaining supply chain efficiency will be crucial for the company's long-term value creation [12].

Group 1: Company Overview - Mingzhi Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CCB International as the sole sponsor [1] - The company specializes in disposable endoscopes and has gained significant attention in the capital market due to its impressive financial metrics, including a gross margin of 72.62% and a net margin of 47.26% for 2024 [1] - Despite its high profitability, the company faces challenges such as high customer concentration, declining cash flow, and increasing market competition [1] Group 2: Business Model and Competitive Advantage - Mingzhi Technology positions itself as a "platform medical device company" with a unique vertical integration model, controlling the entire supply chain from core optical components to system assembly [2] - This vertical integration has resulted in significant cost advantages and technical control, with gross margins increasing from 69.1% in 2023 to 73.7% in the first nine months of 2025 [2][4] - The company has developed competitive products, including some of the thinnest disposable ureteroscopes and cystoscopes, which are crucial for minimally invasive surgeries [2] Group 3: Market Position and Financial Performance - By 2024, Mingzhi Technology ranks among the top three brands in the disposable ureteroscope market in the U.S., Europe, and Japan, reflecting its international competitiveness [3] - The company's revenue for 2024 is projected to be 141.05 million RMB, a 4.4% increase from 2023, but growth has shown signs of slowing down, with only a 3.86% increase in the first nine months of 2025 [3][4] - The gross profit margin has shown a consistent upward trend, but net profit has declined by 14.5% in the first nine months of 2025 compared to the same period in 2024, indicating emerging challenges in profitability [4][11] Group 4: Industry Dynamics and Challenges - The disposable endoscope market is experiencing rapid growth, with projections indicating an expansion from approximately $2 billion in 2023 to over $6 billion by 2030, reflecting a compound annual growth rate of over 17% [8][9] - However, the market is dominated by major players like Ambu, Boston Scientific, and Olympus, which collectively hold over 40% of the global market share, creating significant competitive barriers [9] - Mingzhi Technology's revenue is heavily reliant on overseas markets, exposing it to risks from geopolitical issues, currency fluctuations, and changes in international trade policies [10] Group 5: Operational Risks and Financial Health - The company has a high customer concentration, with the top five customers accounting for 62.6% to 69.9% of sales from 2023 to the first nine months of 2025, indicating a dependency risk [10] - The sales channel structure is heavily reliant on distributors, with 92.8% of revenue coming from this channel in 2024, which may limit direct customer engagement and profit margins [10] - Operational efficiency is under pressure, as evidenced by a 19.45% decline in operating cash flow in the first nine months of 2025, attributed to increased inventory and extended accounts receivable collection periods [11]

融券方面，春立医疗2月10日融券偿还400.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量400.00股，融券余额9184.00元，超过近一年80%分位水平，处于高位。 来源：新浪证券-红岸工作室 2月10日，春立医疗跌0.17%，成交额2656.60万元。两融数据显示，当日春立医疗获融资买入额419.19 万元，融资偿还272.99万元，融资净买入146.20万元。截至2月10日，春立医疗融资融券余额合计 5000.10万元。 融资方面，春立医疗当日融资买入419.19万元。当前融资余额4999.18万元，占流通市值的0.75%，融资 余额超过近一年90%分位水平，处于高位。 分红方面，春立医疗A股上市后累计派现4.40亿元。近三年，累计派现3.90亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167 ...

蓝鲸新闻2月11日讯，近日，吉林证监局发布行政监管措施决定书，剑指迪瑞医疗科技股份有限公司及相关责任人。 决定书显示，迪瑞医疗科技股份有限公司存在以下问题： 一、公司涉外销售订单收入确认不审慎。公司2023年存在部分涉外销售订单确认收入后，对应商品未实际报关并办理退货情形。导致公司2023 年多记营业收入369.30万元，多记营业利润71.60万元。 二、公司涉外销售内部控制不完善，部分涉外销售订单相关资料保存不完整。 ( 令改正行政监管措施并记入证券期货市场诚信档案，对王学敏、牛丹 丹、张兴艳采取出具警示函监管措施并记入证券期货市场诚信档案。 你公司及相关人员应充分汲取教训，严格遵守证券期货法律法规，审 慎执行企业会计准则有关规定,加强公司内部控制,杜绝此类行为再 次发生，并在收到本决定书之日起30日内向我局提交整改报告。 如对本监管措施不服，可在收到本决定书之日起60日内向中国证券监 督管理委员会提出行政复议申请,也可以在收到本决定书之日起6个月 内向有管辖权的人民法院提起行政诉讼。复议与诉讼期间，上述监督 管理措施不停止执行。 吉林证监局 2026年2月5日 上述情况不符合《企业内部控制基本规范》《企业 ...